A307750 Stock Overview
KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
KUKJEON PHARMACEUTICAL Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩6,340.00 |
52 Week High | ₩8,140.00 |
52 Week Low | ₩5,450.00 |
Beta | -1.08 |
1 Month Change | 10.45% |
3 Month Change | 1.60% |
1 Year Change | 5.14% |
3 Year Change | -8.65% |
5 Year Change | n/a |
Change since IPO | -15.58% |
Recent News & Updates
Shareholder Returns
A307750 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | -0.3% | 6.0% | 3.8% |
1Y | 5.1% | 28.8% | 13.0% |
Return vs Industry: A307750 underperformed the KR Pharmaceuticals industry which returned 28.8% over the past year.
Return vs Market: A307750 underperformed the KR Market which returned 13% over the past year.
Price Volatility
A307750 volatility | |
---|---|
A307750 Average Weekly Movement | 5.6% |
Pharmaceuticals Industry Average Movement | 4.8% |
Market Average Movement | 5.3% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A307750 has not had significant price volatility in the past 3 months.
Volatility Over Time: A307750's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | 160 | Jongho Hong | https://www.kukjeon.co.kr |
KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support.
KUKJEON PHARMACEUTICAL Co., Ltd Fundamentals Summary
A307750 fundamental statistics | |
---|---|
Market cap | ₩311.10b |
Earnings (TTM) | ₩4.82b |
Revenue (TTM) | ₩122.00b |
64.5x
P/E Ratio2.6x
P/S RatioIs A307750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A307750 income statement (TTM) | |
---|---|
Revenue | ₩122.00b |
Cost of Revenue | ₩96.72b |
Gross Profit | ₩25.28b |
Other Expenses | ₩20.45b |
Earnings | ₩4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 98.31 |
Gross Margin | 20.72% |
Net Profit Margin | 3.95% |
Debt/Equity Ratio | 80.3% |
How did A307750 perform over the long term?
See historical performance and comparison